AAAAAA

   
Results: 1-8 |
Results: 8
Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice (vol 296, pg 396, 2001)
Authors: Parry, TJ Riccobene, TA Strawn, SJ Williams, R Daoud, R Carrell, J Sosnovtseva, S Miceli, RC Poortman, CM Sekut, L Li, Y Fikes, J Sung, C
Citation: Tj. Parry et al., Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice (vol 296, pg 396, 2001), J PHARM EXP, 297(2), 2001, pp. 827-827
Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice
Authors: Parry, TJ Riccobene, TA Strawn, SJ Williams, R Daoud, R Carrell, J Sosnovtseva, S Miceli, RC Poortman, CM Sekut, L Li, YL Fikes, J Sung, C
Citation: Tj. Parry et al., Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice, J PHARM EXP, 296(2), 2001, pp. 396-404
Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME (TM)) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey
Authors: Sandberg, JA Sproul, CD Blanchard, KS Bellon, L Sweedler, D Powell, JA Caputo, FA Kornbrust, DJ Parker, VP Parry, TJ Blatt, LM
Citation: Ja. Sandberg et al., Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME (TM)) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey, ANTISENSE N, 10(3), 2000, pp. 153-162
Antitumor and antimetastatic activity of ribozymes targeting the messengerRNA of vascular endothelial growth factor receptors
Authors: Pavco, PA Bouhana, KS Gallegos, AM Agrawal, A Blanchard, KS Grimm, SL Jensen, KL Andrews, LE Wincott, FE Pitot, PA Tressler, RJ Cushman, C Reynolds, MA Parry, TJ
Citation: Pa. Pavco et al., Antitumor and antimetastatic activity of ribozymes targeting the messengerRNA of vascular endothelial growth factor receptors, CLIN CANC R, 6(5), 2000, pp. 2094-2103
Ribozymes as tools for therapeutic target validation in arthritis
Authors: Jarvis, TC Bouhana, KS Lesch, ME Brown, SA Parry, TJ Schrier, DJ Hunt, SW Pavco, PA Flory, CM
Citation: Tc. Jarvis et al., Ribozymes as tools for therapeutic target validation in arthritis, J IMMUNOL, 165(1), 2000, pp. 493-498
Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME (TM)) in the mouse
Authors: Sandberg, JA Bouhana, KS Gallegos, AM Agrawal, AB Grimm, SL Wincott, FE Reynolds, MA Pavco, PA Parry, TJ
Citation: Ja. Sandberg et al., Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME (TM)) in the mouse, ANTISENSE N, 9(3), 1999, pp. 271-277
Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA
Authors: Parry, TJ Cushman, C Gallegos, AM Agrawal, AB Richardson, M Andrews, LE Maloney, L Mokler, VR Wincott, FE Pavco, PA
Citation: Tj. Parry et al., Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA, NUCL ACID R, 27(13), 1999, pp. 2569-2577
Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens
Authors: Parry, TJ Pavco, PA Sandberg, JA
Citation: Tj. Parry et al., Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens, INTRACELLULAR RIBOZYME APPLICATIONS, 1999, pp. 231-241
Risultati: 1-8 |